Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ASCO 2023 Expert Report on novelties in oncogene driven NSCLC by A. Curioni-Fontecedro

Reporting from ASCO 2023 Annual Meeting, Alessandra Curioni-Fontecedro summarises the results from three important studies in advanced NSCLC. In the CHRYSALIS 2 study, predictive biomarkers were identified to target the specific population that achieved a remarkable 61% response rate with the combination of amivantamab and lazertinib. The CodeBreaK 200 study investigators conducted a biomarker subgroup analysis identifying KRAS G12C-mutated NSCLC subgroup with co-alterations where sotorasib did not outperform docetaxel. The third study addressed the issue of neoadjuvant osimertinib non-responders in an EGFR-mutated NSCLC population, highlighting the need for further exploration of heterogeneity and other genetic alterations.

Abstracts discussed:
- Abstract 9013: Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.
- Abstract 8508: Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer.
- Abstract 9008: Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.